DMTK - DermTech GAAP EPS of -$0.93 beats by $0.03 revenue of $2.99M beats by $0.43M
- DermTech press release ( NASDAQ: DMTK ): Q4 GAAP EPS of -$0.93 beats by $0.03 .
- Revenue of $2.99M (-5.7% Y/Y) beats by $0.43M .
-
Covered lives increased from 91 million to 124 million and cash runway through the third quarter of 2024
-
Dr. John Dobak will continue to serve as CEO until a successor is appointed
-
Billable sample volume grew 48 percent from the fourth quarter of 2021 to approximately 17,460.
-
Assay revenue was $2.7 million, down 9 percent from the fourth quarter of 2021, primarily due to changes in collection estimates for tests run in prior periods.
For further details see:
DermTech GAAP EPS of -$0.93 beats by $0.03, revenue of $2.99M beats by $0.43M